Epithelial Ovarian Cancer Prevention

  • Setsuko K. ChambersEmail author
  • Lisa M. Hess


Ovarian cancer is the second leading cause of gynecologic cancer death with 238,700 new diagnoses and 151,900 deaths each year worldwide (Torre et al. 2015). In the developed world, ovarian cancer is the leading cause of gynecologic cancer death. In the USA, there are 22,440 new ovarian cancer diagnoses and 14,080 deaths from the disease each year (Siegel et al. 2017). Epithelial ovarian cancers comprise the most common type of ovarian cancers and account for the vast majority of deaths from this disease.

The incidence rate of ovarian cancer varies internationally (Fig. 20.1), with higher rates in Europe and North America and lower rates in Africa and the Middle East. The potential contributing factors related to ovarian cancer risk, early detection and screening, as well as the etiology of the disease are described in more detail in this chapter.


Epithelial ovarian cancer Peritoneal cancer Fallopian tube cancer Symptoms STIC Endometriosis Epigenetics Multidisciplinary clinic 


  1. ACS (2014) American Cancer Society: signs and symptoms of ovarian cancer. Accessed 12 Jan 2018
  2. Anagnostopoulos T, Pertesi M, Konstantopoulou I, Armaou S et al (2008) G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history. Breast Cancer Res Treat 110:377–385PubMedCrossRefPubMedCentralGoogle Scholar
  3. Andersen ES, Knudsen A, Rix P, Johansen B (2003) Risk of Malignancy Index in the preoperative evaluation of patients with adnexal masses. Gynecol Oncol 90(1):109–112PubMedCrossRefPubMedCentralGoogle Scholar
  4. Anderson GL, Limacher M et al (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291(14):1701–1712CrossRefGoogle Scholar
  5. Anveden Å, Taube M, Peltonen M, Jacobson P, Andersson-Assarsson JC, Sjöholm K, Svensson PA, Carlsson LM (2017) Long-term incidence of female-specific cancer after bariatric surgery or usual care in the Swedish Obese Subjects Study. Gynecol Oncol 145(2):224–229PubMedPubMedCentralCrossRefGoogle Scholar
  6. Armstrong K, Schwartz JS, Randall T, Rubin SC, Weber B (2004) Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol 22(6):1045–1054PubMedCrossRefPubMedCentralGoogle Scholar
  7. Auersperg N (2011) The origin of ovarian carinomas: a unifying hypothesis. Int J Gynecol Pathol 30(1):12–21PubMedCrossRefPubMedCentralGoogle Scholar
  8. Austin S, Martin MY, Kim Y, Funkhouser EM, Partridge EE, Pisu M (2012) Disparities in use of gynecologic oncologists for women with ovarian cancer in the United States. Health Serv Res. Scholar
  9. Baandrup L, Faber MT, Christensen J, Jensen A, Andersen KK, Friis S, Kjaer SK (2012) Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies. Acta Obstet Gynecol Scand. Scholar
  10. Barda G, Menczer J et al (2004) Comparison between primary peritoneal and epithelial ovarian carcinoma: a population-based study. Am J Obstet Gynecol 190(4):1039–1045PubMedCrossRefPubMedCentralGoogle Scholar
  11. Barnes MN, Chhieng DF et al (2005) Feasibility of performing chemoprevention trials in women at elevated risk of ovarian carcinoma: initial examination of celecoxib as a chemopreventive agent. Gynecol Oncol 98(3):376–382PubMedCrossRefPubMedCentralGoogle Scholar
  12. Beiner ME, Finch A et al (2007) The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol 104(1):7–10PubMedCrossRefPubMedCentralGoogle Scholar
  13. Beral V, Bull D et al (2007) Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369(9574):1703–1710PubMedCrossRefPubMedCentralGoogle Scholar
  14. Bergman L, Beelen ML et al (2000) Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres’ ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 356(9233):881–887PubMedCrossRefPubMedCentralGoogle Scholar
  15. Bertone ER, Newcomb PA et al (2002a) Recreational physical activity and ovarian cancer in a population-based case-control study. Int J Cancer 99(3):431–436PubMedCrossRefPubMedCentralGoogle Scholar
  16. Bertone ER, Rosner BA et al (2002b) Dietary fat intake and ovarian cancer in a cohort of US women. Am J Epidemiol 156(1):22–31PubMedCrossRefPubMedCentralGoogle Scholar
  17. Biron-Shental T, Drucker L et al (2006) High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma. Eur J Surg Oncol 32(10):1097–1100PubMedCrossRefPubMedCentralGoogle Scholar
  18. Bon GG, Kenemans P et al (1999) Fluctuations in CA 125 and CA 15–3 serum concentrations during spontaneous ovulatory cycles. Hum Reprod 14(2):566–570PubMedCrossRefPubMedCentralGoogle Scholar
  19. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20(5):1248–1259PubMedCrossRefPubMedCentralGoogle Scholar
  20. Broaddus RR, Lynch HT et al (2006) Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer 106(1):87–94PubMedCrossRefPubMedCentralGoogle Scholar
  21. Buamah P (2000) Benign conditions associated with raised serum CA-125 concentration. J Surg Oncol 75(4):264–265PubMedCrossRefPubMedCentralGoogle Scholar
  22. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C et al (2011) Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 305(22):2295–2303PubMedCrossRefPubMedCentralGoogle Scholar
  23. Callahan MJ, Crum CP et al (2007) Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 25(25):3985–3990PubMedCrossRefPubMedCentralGoogle Scholar
  24. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012 Oct;490(7418):61–70. Google Scholar
  25. Capoluongo E, Ellison G, López-Guerrero JA, Penault-Llorca F, Ligtenberg MJ, Banerjee S, Singer C, Friedman E, Markiefka B, Schirmacher P, Büttner R (2017) Guidance statement on BRCA1/2 tumor testing in ovarian cancer patients. Semin Oncol 44(3):187–197PubMedCrossRefPubMedCentralGoogle Scholar
  26. CDC (2017) Centers for Disease Control and Prevention: ovarian cancer rates by race and ethnicity. Accessed 9 Jan 2018
  27. Centers for Disease Control and Prevention; National Center for Health Statistics National Health and Nutrition Examination Survey. Accessed 16 Jan 2018
  28. Chambers SK, Joiner KA (2013) Invited chapter: Incorporating translational research into gynecologic cancers, while balancing the focus of personalized medicine. In: Thomas C, Odunsi K, Pejovic T (eds) Current multidisciplinary oncology. Demos Medical Publishing, New YorkGoogle Scholar
  29. Chen LM, Yang KY et al (2007) Gynecologic cancer prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer families. Obstet Gynecol 110(1):18–25PubMedCrossRefPubMedCentralGoogle Scholar
  30. Choi JH, Wong AS et al (2007) Gonadotropins and ovarian cancer. Endocr Rev 28(4):440–461PubMedCrossRefPubMedCentralGoogle Scholar
  31. Cibula D, Widschwendter M, Majek O, Dusek L (2010) Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum Reprod Update 17(1):55–67PubMedCrossRefPubMedCentralGoogle Scholar
  32. Claus EB, Schildkraut JM et al (1996) The genetic attributable risk of breast and ovarian cancer. Cancer 77(11):2318–2324PubMedCrossRefPubMedCentralGoogle Scholar
  33. Cottreau CM, Ness RB et al (2000) Physical activity and reduced risk of ovarian cancer. Obstet Gynecol 96(4):609–614PubMedPubMedCentralGoogle Scholar
  34. Couzin J (2003) Choices–and uncertainties–for women with BRCA mutations. Science 302(5645):592PubMedCrossRefPubMedCentralGoogle Scholar
  35. Cramer DW (2007) Ovarian cancer early detection biomarkers trials and regulatory issues. EDRN/FDA Education Workshop. Bethesda, Feb 15 2007Google Scholar
  36. Cramer DW, Xu H (1995) Epidemiologic evidence for uterine growth factors in the pathogenesis of ovarian cancer. Ann Epidemiol 5(4):310–314PubMedCrossRefPubMedCentralGoogle Scholar
  37. Cramer DW, Harlow BL et al (1998) Over-the-counter analgesics and risk of ovarian cancer. Lancet 351(9096):104–107PubMedCrossRefPubMedCentralGoogle Scholar
  38. Cramer D, Bast RC, Berg CD et al (2011) Ovarian cancer biomarker performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial specimens. Cancer Prev Res 4(3):365–374CrossRefGoogle Scholar
  39. Cruz VL, Steiner ML, Pompei LM, Strufaldi R, Fonseca FL, Santiago LH, Wajsfeld T, Fernandes CE (2018) Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. Menopause 25(1):21–28PubMedCrossRefPubMedCentralGoogle Scholar
  40. Daly M, Obrams GI (1998) Epidemiology and risk assessment for ovarian cancer. Semin Oncol 25(3):255–264PubMedPubMedCentralGoogle Scholar
  41. Daly MB, Dresher CW, Yates MS, Jeter JM, Karlan BY, Alberts DS, Lu KH (2015) Salpingectomy as a means to reduce ovarian cancer risk. Cancer Prev Res 8(5):342–348CrossRefGoogle Scholar
  42. De Palo G, Veronesi U et al (1995) Can fenretinide protect women against ovarian cancer? J Natl Cancer Inst 87(2):146–147PubMedCrossRefPubMedCentralGoogle Scholar
  43. De Rosa V, Mangoni di Stefano ML et al (1995) Computed tomography and second-look surgery in ovarian cancer patients. Correlation, actual role and limitations of CT scan. Eur J Gynaecol Oncol 16(2):123–129PubMedPubMedCentralGoogle Scholar
  44. Delia D, Aiello A et al (1993) N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 53(24):6036–6041PubMedPubMedCentralGoogle Scholar
  45. DePriest PD, Gallion HH, Pavlik EJ, Kryscio RJ, van Nagell JR Jr (1997) Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecol Oncol 65(3):408–414PubMedCrossRefPubMedCentralGoogle Scholar
  46. Drew SV (2001) Oestrogen replacement therapy and ovarian cancer. Lancet 358(9296):1910PubMedCrossRefPubMedCentralGoogle Scholar
  47. Du XL, Lin CL, Johnson NJ, Altekruse S (2011) Effects of individual-level socioeconomic factors on racial disparities in cancer treatment and survival. Cancer 117(14):3242–3251PubMedPubMedCentralCrossRefGoogle Scholar
  48. Edmondson RJ, Monaghan JM (2001) The epidemiology of ovarian cancer. Int J Gynecol Cancer 11(6):423–429PubMedCrossRefPubMedCentralGoogle Scholar
  49. El-Bayoumy K, Upadhyaya P et al (1995) Chemoprevention of cancer by organoselenium compounds. J Cell Biochem Suppl 22:92–100PubMedCrossRefPubMedCentralGoogle Scholar
  50. Engel C, Loeffler M, Steinke V, Rahne N et al (2012) Risks of less common cancers in proven mutation carriers with Lynch syndrome. J Clin Oncol 30(35):4409–4415PubMedCrossRefPubMedCentralGoogle Scholar
  51. Espey DK, Wu XC et al (2007) Annual report to the nation on the status of cancer, 1975–2004, featuring cancer in American Indians and Alaska Natives. Cancer 110(10):2119–2152PubMedCrossRefPubMedCentralGoogle Scholar
  52. Fackenthal JD, Olopade OI (2007) Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 7(12):937–948PubMedCrossRefPubMedCentralGoogle Scholar
  53. Fairfield KM, Hunter DJ et al (2002) Aspirin, other NSAIDs, and ovarian cancer risk (United States). Cancer Causes Control 13(6):535–542PubMedCrossRefPubMedCentralGoogle Scholar
  54. Falconer H, Yin L, Grönberg H, Altman D (2015) Ovarian cancer risk after salpingectomy: a nationwide population-based study. J Natl Cancer Inst 107(2):dju410PubMedCrossRefPubMedCentralGoogle Scholar
  55. Fathalla MF (1971) Incessant ovulation—a factor in ovarian neoplasia? Lancet 2(7716):163PubMedCrossRefPubMedCentralGoogle Scholar
  56. Febbraro T, Robison K, Wilbur JS, Laprise J, Bregar A, Lopes V, Legare R, Stuckey A (2015) Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals. Gynecol Oncol 138(1):109–114PubMedPubMedCentralCrossRefGoogle Scholar
  57. Ferrandina G, Ranelletti FO et al (2002) Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer. Gynecol Oncol 85(2):305–310PubMedCrossRefPubMedCentralGoogle Scholar
  58. Finch AP, Lubinski J, Møller P, Singer CF, Karlan B, Senter L, Rosen B, Maehle L, Ghadirian P, Cybulski C, Huzarski T (2014) Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 32(15):1547–1553PubMedPubMedCentralCrossRefGoogle Scholar
  59. Flesken-Nikitin A, Hwang CI, Cheng CY, Michurina TV, Enikolopov G, Nikitin AY (2013) Ovarian surface epithelium at the junction area contains a cancerprone stem cell niche. Nature 495(7440):241–245PubMedPubMedCentralCrossRefGoogle Scholar
  60. Formelli F, Cleris L (1993) Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res 53(22):5374–5376PubMedPubMedCentralGoogle Scholar
  61. Foong KW, Bolton H (2017) Obesity and ovarian cancer risk: a systematic review. Post Reprod Health 23(4):183–198PubMedCrossRefPubMedCentralGoogle Scholar
  62. Fredriksson S, Horecka J et al (2008) Multiplexed proximity ligation assays to profile putative plasma biomarkers relevant to pancreatic and ovarian cancer. Clin Chem 54:582–589PubMedCrossRefPubMedCentralGoogle Scholar
  63. Friis S, Nielsen GL et al (2002) Cancer risk in persons receiving prescriptions for paracetamol: a Danish cohort study. Int J Cancer 97(1):96–101PubMedCrossRefPubMedCentralGoogle Scholar
  64. Garg K, Levine DA, Olvera N, Dao F, Bisogna M, Secord AA, Berchuck A, Cerami E, Schultz N, Soslow RA (2013) BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas. Am J Surg Pathol 37(1):138–146PubMedPubMedCentralCrossRefGoogle Scholar
  65. Geomini P, Kruitwagen R, Bremer G, Cnossen J, Mol B (2009) The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet Gynecol 113(2 pt 1):384–394PubMedCrossRefPubMedCentralGoogle Scholar
  66. Gladstone CQ (1994) Screening for ovarian cancer. In: Canadian Task Force on the Periodic Health Examination (ed) Canadian guide to clinical preventive health care. Health Canada, Ottawa, pp 870–881Google Scholar
  67. GLOBOCAN (2012) World Health Organization, International Agency for Research on Cancer.
  68. Goff BA, Mandel LS et al (2004) Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 291(22):2705–2712PubMedCrossRefPubMedCentralGoogle Scholar
  69. Greene MH, Piedmonte M, Alberts DS, Gail M, Hensley M, Miner Z, Mai PL, Loud J, Rodriguez G, Basil J, Boggess J, Schwartz PE, Kelley JL, Wakeley KE, Minasian L, Skates S (2008) A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design & baseline characteristics: a Gynecologic Oncology Group study. Cancer Epidemiol Biomarkers Prev 17:594–604PubMedPubMedCentralCrossRefGoogle Scholar
  70. Hakama M, Stenman UH et al (1996) CA 125 as a screening test for ovarian cancer. J Med Screen 3(1):40–42PubMedCrossRefPubMedCentralGoogle Scholar
  71. Hankinson SE, Colditz GA et al (1995) A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer 76(2):284–290PubMedCrossRefPubMedCentralGoogle Scholar
  72. Hartge P, Hoover R et al (1988) Menopause and ovarian cancer. Am J Epidemiol 127(5):990–998PubMedCrossRefPubMedCentralGoogle Scholar
  73. Hartge P, Struewing JP et al (1999) The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet 64(4):963–970PubMedPubMedCentralCrossRefGoogle Scholar
  74. Havrilesky LJ, Moss HA, Chino J, Myers ER, Kauff ND (2017) Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers. Gynecol Oncol 145(3):549–554PubMedCrossRefPubMedCentralGoogle Scholar
  75. Hess LM, Stehman FB, Method MW, Weathers TD, Gupta P, Schilder JM (2012) Identification of the optimal pathway to reach an accurate diagnosis in the absence of an early detection strategy for ovarian cancer. Gynecol Oncol 127(3):564–568PubMedCrossRefPubMedCentralGoogle Scholar
  76. Hildreth NG, Kelsey JL et al (1981) An epidemiologic study of epithelial carcinoma of the ovary. Am J Epidemiol 114(3):398–405PubMedCrossRefPubMedCentralGoogle Scholar
  77. Holschneider CH, Berek JS (2000) Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 19(1):3–10PubMedCrossRefPubMedCentralGoogle Scholar
  78. Hoyo C, Berchuck A et al (2005) Anthropometric measurements and epithelial ovarian cancer risk in African-American and White women. Cancer Causes Control 16(8):955–963PubMedCrossRefPubMedCentralGoogle Scholar
  79. Huang L, Cronin KA, Johnson KA, Mariotto AB, Feuer EJ (2008) Improved survival time: what can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer? Cancer 112(10):2289–2300PubMedCrossRefPubMedCentralGoogle Scholar
  80. Huncharek M, Kupelnick B (2001) Dietary fat intake and risk of epithelial ovarian cancer: a meta-analysis of 6,689 subjects from 8 observational studies. Nutr Cancer 40(2):87–91PubMedCrossRefPubMedCentralGoogle Scholar
  81. Im SS, Gordon AN, Buttin BM, Leath CA III, Gostout BS, Shah C, Hatch KD, Wang J, Berman ML (2005) Validation of referral guidelines for women with pelvic masses. Obstet Gynecol 105(1):35–41PubMedCrossRefPubMedCentralGoogle Scholar
  82. Jacobs I (1998) Overview–progress in screening for ovarian cancer. In: Sharp F, Blackett A (eds) Ovarian cancer. Isis Medical Media, OxfordGoogle Scholar
  83. Jacobs I, Davies AP et al (1993) Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ 306(6884):1030–1034PubMedPubMedCentralCrossRefGoogle Scholar
  84. Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A et al (2016) Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 387(10022):945–956. Epub 2015 Dec 17CrossRefPubMedPubMedCentralGoogle Scholar
  85. Jarboe E, Folkins A et al (2008) Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol 27(1):1–9PubMedCrossRefPubMedCentralGoogle Scholar
  86. Jelovac D, Armstrong DK (2011) Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 61(3):183–203PubMedPubMedCentralCrossRefGoogle Scholar
  87. John EM, Whittemore AS et al (1993) Characteristics relating to ovarian cancer risk: collaborative analysis of seven U.S. case-control studies. Epithelial ovarian cancer in black women. Collaborative Ovarian Cancer Group. J Natl Cancer Inst 85(2):142–147PubMedCrossRefPubMedCentralGoogle Scholar
  88. Jones S, Wang TL, Shih IM, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B, Kinzler KW, Velculescu VE, Papadopoulos N (2010) Frequent mutations of chromatin remodeling gene ARID1a in ovarian clear cell carcinoma. Science 330(6001):228–231PubMedPubMedCentralCrossRefGoogle Scholar
  89. Joo JE, Dowty JG, Milne RL, Wong EM, Dugué PA, English D, Hopper JL, Goldgar DE, Giles GG, Southey MC (2018) Heritable DNA methylation marks associated with susceptibility to breast cancer. Nat Commun 9(1):867PubMedPubMedCentralCrossRefGoogle Scholar
  90. Junor EJ, Hole DJ, McNulty L, Mason M, Young J (2005) Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. BJOG 106(11):1130–1136CrossRefGoogle Scholar
  91. Kauff ND, Barakat RR (2007) Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol. 25(20):2921–2927PubMedCrossRefPubMedCentralGoogle Scholar
  92. Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, Isaacs C, Evans DG, Lynch H, Eeles RA, Neuhausen SL (2008) Risk-reducing salpingo-oophorectomy for the prevention of BRCA1-and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 26(8):1331–1337PubMedPubMedCentralCrossRefGoogle Scholar
  93. Kedar RP, Bourne TH et al (1994) Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 343(8909):1318–1321PubMedCrossRefPubMedCentralGoogle Scholar
  94. Keita M, Bessette P, Pelmus M, Ainmelk Y, Aris A (2010) Expression of interleukin-1 (IL-1) ligands system in the most common endometriosis-associated ovarian cancer subtypes. J Ovarian Res 3:3PubMedPubMedCentralCrossRefGoogle Scholar
  95. Kerber RA, Slattery ML (1995) The impact of family history on ovarian cancer risk. The Utah Population Database. Arch Intern Med 155(9):905–912PubMedCrossRefPubMedCentralGoogle Scholar
  96. Key TJ, Appleby PN et al (2003) Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 95(16):1218–1226PubMedCrossRefPubMedCentralGoogle Scholar
  97. Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM, Matzuk MM (2012) High grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc NAS 109(10):3921–3926CrossRefGoogle Scholar
  98. Kim J, Coffey DM, Ma L, Matzuk MM (2015) The ovary is an alternative site of origin for high-grade serous ovarian cancer in mice. Endocrinology 156(6):1975–1981PubMedPubMedCentralCrossRefGoogle Scholar
  99. King MC, Marks JH et al (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645):643–646PubMedPubMedCentralGoogle Scholar
  100. Kjaerbye-Thygesen A, Frederiksen K et al (2006) Do risk factors for epithelial ovarian cancer have an impact on prognosis? Focus on previous pelvic surgery and reproductive variables. Eur J Gynaecol Oncol 27(5):467–472PubMedPubMedCentralGoogle Scholar
  101. Kobayashi H, Yamada Y, Sado T, Sakata M, Yoshida S, Kawaguchi R et al (2008) A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer Soc 18(3):414–420CrossRefGoogle Scholar
  102. Koifman S, Jorge Koifman R (2001) Breast cancer mortality among Ashkenazi Jewish women in Sao Paulo and Porto Alegre, Brazil. Breast Cancer Res 3(4):270–275PubMedPubMedCentralCrossRefGoogle Scholar
  103. Kosary CL (2007) Cancer of the ovary. In: Ries LAG, Young JL, Keel GE et al (eds) SEER survival monograph: cancer survival among adults: U.S. SEER Program, 1988–2001, patient and tumor characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215, BethesdaGoogle Scholar
  104. Koshiyama M et al (2016) Clinical efficacy of ovarian cancer screening. J Cancer 7(10):1311–1316PubMedPubMedCentralCrossRefGoogle Scholar
  105. Kozak KR, Amneus MW et al (2003) Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci U S A 100(21):12343–12348PubMedPubMedCentralCrossRefGoogle Scholar
  106. Kozak KR, Su F et al (2005) Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 5(17):4589–4596PubMedCrossRefPubMedCentralGoogle Scholar
  107. Kuhn E, Kurman RJ, Vang R, Sedev AS, Han G, Soslow R, T-L W, Shih L-M (2012) TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serious carcinoma—evidence supporting the clonal relationship of the two lesions. J Pathol 226(3):421–426PubMedCrossRefPubMedCentralGoogle Scholar
  108. Kumle M, Alsaker E et al (2003) Use of oral contraceptives and risk of cancer, a cohort study. Tidsskr Nor Laegeforen 123(12):1653–1656PubMedPubMedCentralGoogle Scholar
  109. Kurman RJ, Shih IM (2011) Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer–shifting the paradigm. Hum Pathol 42(7):918–931PubMedPubMedCentralCrossRefGoogle Scholar
  110. Kwon JS, McAlpine JN, Hanley GE, Finlayson SJ, Cohen T, Miller DM, Gilks CB, Huntsman DG (2015) Costs and benefits of opportunistic salpingectomy as an ovarian cancer prevention strategy. Obstet Gynecol 125(2):338–345PubMedCrossRefPubMedCentralGoogle Scholar
  111. Lacey JV, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, Schatzkin A, Schairer C (2002) Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288(3):334–341PubMedCrossRefPubMedCentralGoogle Scholar
  112. Landen CN, Birrer MJ, Sood AK (2008) Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 26(6):995–1005PubMedCrossRefPubMedCentralGoogle Scholar
  113. Larsson SC, Wolk A (2005) No association of meat, fish, and egg consumption with ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 14(4):1024–1025PubMedCrossRefPubMedCentralGoogle Scholar
  114. Lavie O, Hornreich G et al (2004) BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecol Oncol 92(2):521–524PubMedCrossRefPubMedCentralGoogle Scholar
  115. Lee Y, Miron A et al (2007) A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 211(1):26–35PubMedCrossRefPubMedCentralGoogle Scholar
  116. Levy-Lahad E, Friedman E (2007) Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer 96(1):11–15PubMedPubMedCentralCrossRefGoogle Scholar
  117. Li J, Abushahin N, Pang S, Xiang L, Chambers S, Fadare O, Kong B, Zheng W (2011) Tubal origin of ‘ovarian’ low-grade serous carcinoma. Mod Pathol 24:1488–1499PubMedCrossRefPubMedCentralGoogle Scholar
  118. Li Y, Li Y, Zhang J, Zheng C, Zhu H, Yu H, Fan L (2016) Circulating insulin-like growth factor-1 level and ovarian cancer risk. Cell Physiol Biochem 38(2):589–597PubMedCrossRefPubMedCentralGoogle Scholar
  119. Lim AW, Mesher D, Gentry-Maharaj A, Balogun N, Jacobs I, MenonU SP (2012) Predictive value of symptoms for ovarian cancer: comparison of symptoms reported by questionnaire, interview and general practitioner notes. J Natl Cancer Inst 104(2):114–124PubMedCrossRefPubMedCentralGoogle Scholar
  120. Lipsett MB (1979) Interaction of drugs, hormones, and nutrition in the causes of cancer. Cancer 43(5 Suppl):1967–1981PubMedCrossRefPubMedCentralGoogle Scholar
  121. Lu KH, Daniels M (2013) Endometrial and ovarian cancer in women with lynch syndrome: update in screening and prevention. Fam Cancer 12(2):273–277. Scholar
  122. Mackenzie R, Kommoss S, Winterhoff BJ, Kipp BR, Garcia JJ, Voss J, Halling K, Karnezis A, Senz J, Yang W, Prigge ES (2015) Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. BMC Cancer 15(1):415PubMedPubMedCentralCrossRefGoogle Scholar
  123. Madalinska JB, Hollenstein J, Bleike E et al (2005) Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk or hereditary ovarian cancer. J Clin Oncol 23(28):6890–6898PubMedCrossRefPubMedCentralGoogle Scholar
  124. Madsen C, Baandrup L, Dehlendorff C, Kjær SK (2015) Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderlineovarian tumors: a nationwide case–control study. Acta Obstet Gynecol Scand 94:86–94PubMedCrossRefPubMedCentralGoogle Scholar
  125. Malik IA (2002) A prospective study of clinico-pathological features of epithelial ovarian cancer in Pakistan. J Pak Med Assoc 52(4):155–158PubMedPubMedCentralGoogle Scholar
  126. Mansfield CM (1993) A review of the etiology of breast cancer. J Natl Med Assoc 85(3):217–221PubMedPubMedCentralGoogle Scholar
  127. Maringe C, Walters S, Butler J, Coleman MP, Hacker N, Hanna L, Mosgaard BJ, Nordin A et al (2012) Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership. Gynecol Oncol 127(1):75–82PubMedCrossRefPubMedCentralGoogle Scholar
  128. Matsumoto T, Yamazaki M, Takahashi H, Kajita S, Suzuki E, Tsuruta T, Saegusa M (2015) Distinct beta-catenin and PIK3CA mutation profiles in endometriosis-associated ovarian endometrioid and clear cell carcinomas. Amer J Clin Path 144(3):452–463CrossRefGoogle Scholar
  129. McAlpine JN, Hanley GE, Woo MMM et al (2014) Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol 210:471.e1–471.11CrossRefGoogle Scholar
  130. McClain MR, Palomaki GE et al (2005) Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications. Genet Med 7(1):28–33PubMedCrossRefPubMedCentralGoogle Scholar
  131. McGowan L, Lesher LP, Norris HJ, Barnett M (1985) Misstaging of ovarian cancer. Obstet Gynecol 65(4):568–572PubMedPubMedCentralGoogle Scholar
  132. McGuire V, Herrinton L et al (2002) Race, epithelial ovarian cancer survival, and membership in a large health maintenance organization. Epidemiology 13(2):231–234PubMedCrossRefPubMedCentralGoogle Scholar
  133. Menon U, Skates SJ, Lewis S, Rosenthal AN, Rufford B, Sibley K et al (2005) Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 23(31):7919–7926PubMedCrossRefPubMedCentralGoogle Scholar
  134. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A et al (2009) Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 10(4):327–340PubMedCrossRefPubMedCentralGoogle Scholar
  135. Merrill RM (2006) Impact of hysterectomy and bilateral oophorectomy on race-specific rates of corpus, cervical, and ovarian cancers in the United States. Ann Epidemiol 16(12):880–887PubMedCrossRefPubMedCentralGoogle Scholar
  136. Meyer T, Rustin GJ (2000) Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 82(9):1535–1538PubMedPubMedCentralCrossRefGoogle Scholar
  137. Modesitt SC, van Nagell JR Jr (2005) The impact of obesity on the incidence and treatment of gynecologic cancers: a review. Obstet Gynecol Surv 60(10):683–692PubMedCrossRefPubMedCentralGoogle Scholar
  138. Mor G, Visintin I et al (2005) Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A 102(21):7677–7682PubMedPubMedCentralCrossRefGoogle Scholar
  139. Mørch LS, Løkkegaard E, Andreasen AH, Krüger-Kjær S, Lidegaard Ø (2009) Hormone therapy and ovarian cancer. JAMA 302(3):298–305PubMedCrossRefPubMedCentralGoogle Scholar
  140. Morrison J, Bronner M, Leach BH, Downs-Kelly E, Goldblum JR, Liu X (2011) Lynch syndrome screening in newly diagnosed colorectal cancer in general pathology practice. Scand J Gastroenterol 46:1340–1348PubMedCrossRefPubMedCentralGoogle Scholar
  141. Muka T, Oliver-Williams C, Kunutsor S, Laven JS, Fauser BC, Chowdhury R (2016) Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. JAMA Cardiol 1(7):767–776PubMedCrossRefPubMedCentralGoogle Scholar
  142. Murdoch WJ, McDonnel AC (2002) Roles of the ovarian surface epithelium in ovulation and carcinogenesis. Reproduction 123(6):743–750PubMedCrossRefPubMedCentralGoogle Scholar
  143. Murphy MA, Wentzensen N (2011) Frequency of mismatch repair deficiency in ovarian cancer: a systematic review. Int J Cancer 129(8):1914–1922. Scholar
  144. Nagle CM, Olsen CM, Webb PM, Jordan SJ, Whiteman DC, Green AC (2008) Endometrioid and clear cell ovarian cancers: a comparative analysis of risk factors. Eur J Cancer 44(16):2477–2484PubMedCrossRefPubMedCentralGoogle Scholar
  145. Nagle CM, Francis JE, Nelson AE, Zorbas H, Luxford K, De Fazio A, Fereday S, Bowtell DD, Green AC, Webb PM (2011) Reducing time to diagnosis does not improve outcomes for women with symptomatic ovarian cancer: a report from the Australian Ovarian cancer Study Group. J Clin Oncol 29(16):2253–2258PubMedCrossRefPubMedCentralGoogle Scholar
  146. NAS-National Academies of Sciences, Engineering, and Medicine (2016) Ovarian cancers: evolving paradigms in research and care. The National Academies Press, Washington, DC. Scholar
  147. Narod SA, Risch H et al (1998) Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 339(7):424–428PubMedPubMedCentralCrossRefGoogle Scholar
  148. Narod SA, Dube MP et al (2002) Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94(23):1773–1779PubMedCrossRefPubMedCentralGoogle Scholar
  149. Negri E, Franceschi S et al (1991) Pooled analysis of 3 European case-control studies: I. Reproductive factors and risk of epithelial ovarian cancer. Int J Cancer 49(1):50–56PubMedCrossRefPubMedCentralGoogle Scholar
  150. Nelson HD, Vesco KK et al (2006) Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 295(17):2057–2071PubMedCrossRefPubMedCentralGoogle Scholar
  151. Nelson-Moseke AC, Jeter JM, Cui H, Roe DJ, Chambers SK, Laukaitis CM (2013) An unusual BRCA mutation distribution in a high risk cancer genetics clinic. Fam Cancer 12:83–87PubMedPubMedCentralCrossRefGoogle Scholar
  152. Ness RB, Grisso JA et al (2000) Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions. Am J Epidemiol 152(3):233–241PubMedCrossRefPubMedCentralGoogle Scholar
  153. Ness RB, Cramer DW et al (2002) Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 155(3):217–224PubMedCrossRefPubMedCentralGoogle Scholar
  154. Neuhausen SL (2000) Founder populations and their uses for breast cancer genetics. Breast Cancer Res 2(2):77–81PubMedPubMedCentralCrossRefGoogle Scholar
  155. Ng A, Barker N (2015) Ovary and fimbrial stem cells: Biology, niche and cancer origins. Nat Rev Mol Cell Biol 16(10):625–638PubMedCrossRefPubMedCentralGoogle Scholar
  156. NIH Consensus Conference (1995) Ovarian cancer. Screening, treatment, and follow-up. NIH consensus development panel on ovarian cancer. JAMA 273(6):491–497CrossRefGoogle Scholar
  157. Nolen BM, Lokshin AE (2012) Protein biomarkers of ovarian cancer: the forest and the trees. Future Oncol 8(1):55–71PubMedPubMedCentralCrossRefGoogle Scholar
  158. O’Malley CD, Shema SJ, Cress RD, Bauer K, Kahn AR, Schymura MJ, Wike JM, Stewart SL (2012) The implications of age and comorbidity on survival following epithelial ovarian cancer: summary and results from a Centers for Disease Control and Prevention Study. J Womens Health 21(9):887–894CrossRefGoogle Scholar
  159. Olivier RI, Lubsen-Brandsma MA et al (2006) CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol 100(1):20–26PubMedCrossRefPubMedCentralGoogle Scholar
  160. Ong JS et al (2016) Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. Int J Epidemiol 45(5):1619–1630. Scholar
  161. Ose J, Fortner RT, Schock H, Peeters PH, Onland-Moret NC, Bueno-de-Mesquita HB, Weiderpass E, Gram IT, Overvad K, Tjonneland A, Dossus L (2015) Insulin-like growth factor I and risk of epithelial invasive ovarian cancer by tumour characteristics: results from the EPIC cohort. Br J Cancer 112(1):162–166PubMedCrossRefPubMedCentralGoogle Scholar
  162. Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, Chen JY, Ohman AW, Stepule CD, Kwak S, Karst AM, Hirsch MS, Setlur SR, Crum CP, Dinulescu DM, Drapkin R (2013) Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 24(6):751–765PubMedPubMedCentralCrossRefGoogle Scholar
  163. Piver MS, Jishi MF et al (1993) Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 71(9):2751–2755PubMedCrossRefPubMedCentralGoogle Scholar
  164. Ponzoni M, Bocca P et al (1995) Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Res 55(4):853–861PubMedPubMedCentralGoogle Scholar
  165. Portman D (2013) Outcome of the visual evaluation of the vagina in phase 3 studies of oral ospemifene for vulvar/vaginal atrophy. J Sex Med 10:166Google Scholar
  166. Prentice RL, Thomson CA et al (2007) Low-fat dietary pattern and cancer incidence in the Women’s Health Initiative Dietary Modification Randomized Controlled Trial. J Natl Cancer Inst 99(20):1534–1543PubMedPubMedCentralCrossRefGoogle Scholar
  167. Protani MM, Nagle CM, Webb PM (2012) Obesity and ovarian cancer survival: a systematic review and meta-analysis. Cancer Prev Res 5(7):901–910CrossRefGoogle Scholar
  168. Rapkiewicz AV, Espina V et al (2004) Biomarkers of ovarian tumours. Eur J Cancer 40(17):2604–2612PubMedCrossRefPubMedCentralGoogle Scholar
  169. Rebbeck TR (2000) Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 18(21 Suppl):100S–103SPubMedPubMedCentralGoogle Scholar
  170. Rebbeck TR, Friebel T et al (2005) Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 23(31):7804–7810PubMedPubMedCentralCrossRefGoogle Scholar
  171. Rebbeck TR, Troxel AB et al (2007) A retrospective case-control study of the use of hormone-related supplements and association with breast cancer. Int J Cancer 120(7):1523–1528PubMedCrossRefPubMedCentralGoogle Scholar
  172. Rechsteiner M, Zimmermann AK, Wild PJ, Caduff R, von Teichman A, Fink D, Moch H, Noske A (2013) TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Exp Mol Pathol 95(2):235–241PubMedCrossRefPubMedCentralGoogle Scholar
  173. Ricciardelli C, Oehler MK (2009) Diverse molecular pathways in ovarian cancer and their clinical significance. Maturitas 62(3):270–275PubMedCrossRefPubMedCentralGoogle Scholar
  174. Rice MS, Murphy MA, Tworoger SS (2012) Tubal ligation, hysterectomy and ovarian cancer: a meta-analysis. J Ovarian Res 5:13PubMedPubMedCentralCrossRefGoogle Scholar
  175. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Feuer EJ, Edwards BK (2004) SEER cancer statistics review, 1995–2001. National Cancer Institute, BethesdaGoogle Scholar
  176. Ries LAG, Eisner MP, Kosary CL et al (2005) SEER cancer statistics review, 1975–2002. Retrieved 13 Feb 2007
  177. Riman T, Dickman PW et al (2002) Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol 156(4):363–373PubMedCrossRefPubMedCentralGoogle Scholar
  178. Risch HA (1998) Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90(23):1774–1786PubMedCrossRefPubMedCentralGoogle Scholar
  179. Risch HA, Marrett LD et al (1994) Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol 140(7):585–597PubMedCrossRefPubMedCentralGoogle Scholar
  180. Rodriguez GC, Walmer DK et al (1998) Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Investig 5(5):271–276PubMedPubMedCentralGoogle Scholar
  181. Rodriguez C, Patel AV et al (2001) Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 285(11):1460–1465PubMedCrossRefPubMedCentralGoogle Scholar
  182. Rodriguez-Burford C, Barnes MN et al (2002) Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res 8(1):202–209PubMedPubMedCentralGoogle Scholar
  183. Rosenblatt KA, Thomas DB (1996) Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Cancer Epidemiol Biomarkers Prev 5(11):933–935PubMedPubMedCentralGoogle Scholar
  184. Ross SA, Dwyer J, Umar A, Kagan J, Verma M, Van Bemmel DM, Dunn BK (2008) Introduction: diet, epigenetic events and cancer prevention. Nutr Rev 66(Suppl 1):S1–S6PubMedPubMedCentralCrossRefGoogle Scholar
  185. Sakoda LC, Jorgenson E, Witte JS (2013) Turning of COGS moves forward findings for hormonally mediated cancers. Nat Genet 45(4):345–348PubMedCrossRefPubMedCentralGoogle Scholar
  186. Salvador S, Gilks B et al (2009) The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer 19(1):58–64PubMedCrossRefPubMedCentralGoogle Scholar
  187. Santin AD, Bellone S, Van Stedum S, Bushen W, Luis E, Korourian S, Tian E, Roman JJ, Burnett A, Pecorelli S (2005) Determination of HER2/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecol Oncol 98(1):24–30PubMedCrossRefPubMedCentralGoogle Scholar
  188. Saslow D, Boetes C et al (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57(2):75–89PubMedPubMedCentralCrossRefGoogle Scholar
  189. Schildkraut JM, Cooper GS et al (2001) Age at natural menopause and the risk of epithelial ovarian cancer. Obstet Gynecol 98(1):85–90PubMedPubMedCentralGoogle Scholar
  190. Sellers TA, Gapstur SM et al (1993) Association of body fat distribution and family histories of breast and ovarian cancer with risk of postmenopausal breast cancer. Am J Epidemiol 138(10):799–803PubMedCrossRefPubMedCentralGoogle Scholar
  191. SGO (2005) Clinical Practice Committee Statement on Prophylactic Salpingo-oophorectomy. The Society of Gynecologic Oncologists. Gynecol Oncol 98(2):179–191CrossRefGoogle Scholar
  192. SGO (2014) Society of Gynecologic Oncologists Clinical Practice Statement: genetic testing for ovarian cancer. https://wwwsgoorg/clinical-practice/guidelines/genetic-testing-for-ovarian-cancer/. Accessed 17 Jan 2018
  193. Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA, Nathanson KL, Konner JA, Arnold AG, Bogomolniy F, Dao F (2016) Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncol 2(11):1434–1440PubMedPubMedCentralCrossRefGoogle Scholar
  194. Siskind V, Green A et al (2000) Beyond ovulation: oral contraceptives and epithelial ovarian cancer. Epidemiology 11(2):106–110PubMedCrossRefPubMedCentralGoogle Scholar
  195. Sit AS, Modugno F et al (2002) Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma. Gynecol Oncol 86(2):118–123PubMedCrossRefPubMedCentralGoogle Scholar
  196. Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, Ivanov I, Bell MC, Blank SV, DiSilvestro P, Hamilton CA (2014) Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol 32(29):3275–3283PubMedPubMedCentralCrossRefGoogle Scholar
  197. Skates SJ, Mai P, Horick NK, Piedmonte M et al (2011) Large prospective study of ovarian cancer screening in high-risk women: CA-125 cut-point defined by menopausal status. Cancer Prev Res 4(9):1401–1408CrossRefGoogle Scholar
  198. Song H, Ramus SJ, Tyrer J et al (2009) A genome-wide association study identified a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 41:996–1000PubMedPubMedCentralCrossRefGoogle Scholar
  199. Stanford JL (1991) Oral contraceptives and neoplasia of the ovary. Contraception 43(6):543–556PubMedCrossRefPubMedCentralGoogle Scholar
  200. Supino R, Crosti M et al (1996) Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. Int J Cancer 65(4):491–497PubMedCrossRefPubMedCentralGoogle Scholar
  201. Takahashi K, Eda Y et al (1993) Morphological assessment of polycystic ovary using transvaginal ultrasound. Hum Reprod 8(6):844–849PubMedCrossRefPubMedCentralGoogle Scholar
  202. Tang S, Onuma K, Deb P, Wang E, Lytwyn A, Sur M, Daya D (2012) Frequency of serous tubal intraepithelial carcinoma in various gynecologic malignancies: a study of 300 consecutive cases. Int J Gynecol Pathol 31(2):103–110PubMedCrossRefPubMedCentralGoogle Scholar
  203. Tavani A, Gallus S et al (2000) Aspirin and ovarian cancer: an Italian case-control study. Ann Oncol 11(9):1171–1173PubMedCrossRefPubMedCentralGoogle Scholar
  204. Thompson HJ, Wilson A et al (1994) Comparison of the effects of an organic and an inorganic form of selenium on a mammary carcinoma cell line. Carcinogenesis 15(2):183–186PubMedCrossRefPubMedCentralGoogle Scholar
  205. Thompson HJ, Jiang C et al (1997) Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res 57(2):267–271PubMedPubMedCentralGoogle Scholar
  206. Tice JA, Grady D (2006) Alternatives to estrogen for treatment of hot flashes: are they effective and safe? JAMA 295(17):2076–2078PubMedCrossRefPubMedCentralGoogle Scholar
  207. Tobacman JK, Greene MH et al (1982) Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet 2(8302):795–797PubMedCrossRefPubMedCentralGoogle Scholar
  208. Toma S, Isnardi L et al (1997) Effects of all-trans-retinoic acid and 13-cis-retinoic acid on breast-cancer cell lines: growth inhibition and apoptosis induction. Int J Cancer 70(5):619–627PubMedCrossRefPubMedCentralGoogle Scholar
  209. Trabert B, Coburn SB, Mariani A, Yang HP, Rosenberg PS, Gierach GL, Wentzensen N, Cronin KA, Sherman ME (2017) Reported incidence and survival of fallopian tube carcinomas: a population-based analysis from the North American Association of Central Cancer Registries. J Natl Cancer Inst 110(7):750–757PubMedCentralCrossRefGoogle Scholar
  210. Twombly R (2007) Cancer killer may be “silent” no more. J Natl Cancer Inst 99(18):1359–1361PubMedCrossRefPubMedCentralGoogle Scholar
  211. US Preventive Services Task Force (2004) Screening for ovarian cancer: recommendation statement. Ann Family Med. 2(3):260–262CrossRefGoogle Scholar
  212. USPSTF (2012) Addendum to screening for ovarian cancer: evidence update for the U.S. Preventive Services Task Force Reaffirmation Recommendation Statement. Accessed 12 May 12
  213. USPSTF (2013) Screening for ovarian cancer: reaffirmation recommendation statement. Am Fam Physician 87(10):OnlineGoogle Scholar
  214. Vachon CM, Mink PJ et al (2002) Association of parity and ovarian cancer risk by family history of breast or ovarian cancer in a population-based study of postmenopausal women. Epidemiology 13(1):66–71PubMedCrossRefPubMedCentralGoogle Scholar
  215. van der Burg ME, Lammes FB et al (1993) The role of CA 125 and conventional examinations in diagnosing progressive carcinoma of the ovary. Surg Gynecol Obstet 176(4):310–314PubMedPubMedCentralGoogle Scholar
  216. van Nagell JR Jr, PD DP, Ueland FR, CP DS, Cooper AL, JM MD et al (2007) Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer 109(9):1887–1896PubMedCrossRefPubMedCentralGoogle Scholar
  217. van Nagell JR Jr, Miller RW, CP DS, Ueland FR, Podzielinski I, Goodrich ST, Elder JW, Huang B, Kryscio RJ, Pavlik EJ (2011) Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening. Obstet Gynecol 118(6):1212–1221PubMedCrossRefPubMedCentralGoogle Scholar
  218. Vang R, Shih IM, Kurman RJ (2009) Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 16(5):267PubMedPubMedCentralCrossRefGoogle Scholar
  219. Verheijen RH, von Mensdorff-Pouilly S et al (1999) CA 125: fundamental and clinical aspects. Semin Cancer Biol 9(2):117–124PubMedCrossRefPubMedCentralGoogle Scholar
  220. Walker GR, Schlesselman JJ et al (2002) Family history of cancer, oral contraceptive use, and ovarian cancer risk. Am J Obstet Gynecol 186(1):8–14PubMedCrossRefPubMedCentralGoogle Scholar
  221. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, Roeb W, Agnew KJ, Stray SM, Wickramanayake A, Norquist B (2011) Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci 108(44):18032–18037PubMedCrossRefPubMedCentralGoogle Scholar
  222. Weitzel JN, Lagos V et al (2005) Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev 14(7):1666–1671PubMedCrossRefPubMedCentralGoogle Scholar
  223. Welcsh PL, King MC (2001) BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 10(7):705–713PubMedCrossRefPubMedCentralGoogle Scholar
  224. Wen W, Xiao N, Bender R, Ghazalpour A, Tan Z, Swensen J, Millis SZ, Basu G, Gatalica Z, Press MF (2015) Mutations in the kinase domain of the HER2/ErbB2 gene identified in a wide variety of human cancers. J Mol Diagn 17(5):487–495PubMedPubMedCentralCrossRefGoogle Scholar
  225. Widschwendter M, Jones A, Teschendorff AE (2013) Epigenetics makes its mark on women-specific cancers—an opportunity to redefine oncological approaches? Gynecol Oncol 128(1):134–143PubMedCrossRefPubMedCentralGoogle Scholar
  226. Whittemore AS, Harris R et al (1992) Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer Collaborative Ovarian Cancer Group. Am J Epidemiol 136(10):1212–1220PubMedCrossRefPubMedCentralGoogle Scholar
  227. Wu ML, Whittemore AS et al (1988) Personal and environmental characteristics related to epithelial ovarian cancer. I. Reproductive and menstrual events and oral contraceptive use. Am J Epidemiol 128(6):1216–1227PubMedCrossRefPubMedCentralGoogle Scholar
  228. Yancik R (1993) Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 71(2 Suppl):517–523PubMedPubMedCentralGoogle Scholar
  229. Youngson NA, Morris MJ (2013) What obesity research tells us about epigenetic mechanisms. Philos Trans R Soc B 368:20110337CrossRefGoogle Scholar
  230. Yoon SH, Kim SN, Shim SH, Kang SB, Lee SJ (2016) Bilateral salpingectomy can reduce the risk of ovarian cancer in the general population: a meta-analysis. Eur J Cancer 55:38–46PubMedCrossRefPubMedCentralGoogle Scholar
  231. Zhang M, Yang ZY et al (2002) Diet and ovarian cancer risk: a case-control study in China. Br J Cancer 86(5):712–717PubMedPubMedCentralCrossRefGoogle Scholar
  232. Zhang M, Xie X et al (2005) Body mass index in relation to ovarian cancer survival. Cancer Epidemiol Biomarkers Prev 14(5):1307–1310PubMedCrossRefPubMedCentralGoogle Scholar
  233. Zhang S, Lu Z, Unruh AK, Ivan C, Baggerly KA, Calin GA, Li Z, Bast RC Jr, Le XF (2015) Clinically relevant microRNAs in ovarian cancer. Mol Cancer Res 13(3):393–401PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyCollege of Medicine, University of Arizona, and University of Arizona Cancer CenterTucsonUSA
  2. 2.Department of Obstetrics and GynecologySchools of Medicine and Public Health, Indiana UniversityIndianapolisUSA

Personalised recommendations